Ensysce Biosciences And 2 Other Stocks Under $2 Insiders Are Aggressively Buying

Benzinga - The Dow Jones rose around 40 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Ensysce Biosciences

• The Trade: Ensysce Biosciences, Inc. (NASDAQ: ENSC) Director Bob G Gower bought a total of 90,287 shares at an average price of $0.49. To acquire these shares, it cost around $44.09 thousand.
• What’s Happening: Ensysce Biosciences announced critical step in human abuse potential study of PF614 with database lock.
• What Ensysce Biosciences Does: Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs.

Global Clean Energy Holdings

• The Trade: Global Clean Energy Holdings, Inc. (OTC: GCEH) 10% owner Michael Zilkha acquired a total 141,020 shares at an average price of $0.56. The insider spent around $78.97 thousand to buy those shares.
• What’s Happening: The company’s stock tumbled 57% over the past six months.
• What Global Clean Energy Holdings Does: Global Clean Energy Holdings Inc is a United States-based energy agri-business focused on the development of ultra-low carbon non-food based feedstocks for renewable fuels and chemicals in the US, Mexico, and the Caribbean.

Castellum

• The Trade: Castellum, Inc. (NYSE: CTM) 10% owner Jay Wright acquired a total of 30,100 shares at an average price of $1.00. To acquire these shares, it cost around $29.98 thousand.
• What’s Happening: Castellum recently reported a $500,000 Equity financing.
• What Castellum Does: Castellum Inc, formerly BioNovelus Inc is engaged in acquiring and growing technology companies in the areas of information technology and cybersecurity with businesses in the public (government) and private (commercial) markets.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga